LOGIN  |  REGISTER
Astria Therapeutics

Avanos Medical to Present at the Stifel 2023 Healthcare Conference

November 07, 2023 | Last Trade: US$16.08 0.46 -2.78

ALPHARETTA, Ga., Nov. 7, 2023 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer, will participate in an analyst-led fireside chat at the Stifel 2023 Healthcare Conference on Tuesday, Nov. 14 at approximately 10:20 a.m. ET.

A webcast of the conference presentation will be available on the Investors section of the Avanos Medical website and will be archived on that site.

About Avanos Medical, Inc.

Avanos Medical, Inc. (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. We develop, manufacture and market our recognized brands globally and hold leading market positions in multiple categories across our portfolio. For more information, visit Avanos.com and follow Avanos Medical on Twitter (@AvanosMedical), LinkedIn and Facebook.

Chimerix

Stock Quote

Featured Stock

Recursion

Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB